[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004062607A3 - Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb - Google Patents

Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb Download PDF

Info

Publication number
WO2004062607A3
WO2004062607A3 PCT/US2004/000544 US2004000544W WO2004062607A3 WO 2004062607 A3 WO2004062607 A3 WO 2004062607A3 US 2004000544 W US2004000544 W US 2004000544W WO 2004062607 A3 WO2004062607 A3 WO 2004062607A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
precursors
tuberculosis
weak acids
drug resistant
Prior art date
Application number
PCT/US2004/000544
Other languages
French (fr)
Other versions
WO2004062607A2 (en
Inventor
Ying Zhang
Original Assignee
Ying Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ying Zhang filed Critical Ying Zhang
Publication of WO2004062607A2 publication Critical patent/WO2004062607A2/en
Publication of WO2004062607A3 publication Critical patent/WO2004062607A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to the use of weak acids or weak acid precursors as prodrugs for the treatment of tuberculosis (TB). In addition, the present invention is directed to the use of weak acids or their precursors in combination with the current TB drugs such as isoniazid, rifampin, pyrazinamide, ethambutol for the treatment and prevention of TB or drug-resistant TB and for shortening the duration of the treatment.
PCT/US2004/000544 2003-01-13 2004-01-12 Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb WO2004062607A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43945403P 2003-01-13 2003-01-13
US60/439,454 2003-01-13

Publications (2)

Publication Number Publication Date
WO2004062607A2 WO2004062607A2 (en) 2004-07-29
WO2004062607A3 true WO2004062607A3 (en) 2005-11-10

Family

ID=32713485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000544 WO2004062607A2 (en) 2003-01-13 2004-01-12 Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb

Country Status (1)

Country Link
WO (1) WO2004062607A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT103495B (en) * 2006-06-05 2017-05-12 Faculdade De Farmácia Da Univ De Lisboa PRO-DRUGS OF ORGANIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE PRE-DRUGS
EA201390424A1 (en) 2010-09-20 2013-07-30 Круселл Холланд Б.В. THERAPEUTIC VACCINATION AGAINST ACTIVE TUBERCULOSIS
AP2013006986A0 (en) 2011-01-04 2013-07-31 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
GB201103453D0 (en) 2011-03-01 2011-04-13 Vib Vzw Kinase substrate sensor
CN102357249A (en) * 2011-10-26 2012-02-22 广州赫尔氏药物开发有限公司 Medicine for inhibiting medicine-resistant tubercle bacillus
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104640855B (en) 2012-06-28 2017-08-29 诺华股份有限公司 Complement is by way of conditioning agent and application thereof
ES2647124T3 (en) 2012-06-28 2017-12-19 Novartis Ag Pyrrolidine derivatives and their use as modulators of the complement pathway
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
IN2015DN00185A (en) 2012-07-12 2015-06-12 Novartis Ag
KR101795115B1 (en) * 2014-02-03 2017-11-08 최원형 Anti-tuberculosis composition for treating or preventing tuberculosis comprising gamma-Linolenic acid
DE102014013241A1 (en) * 2014-09-11 2016-03-17 Bode Chemie Gmbh Tuberculocidal disinfectant
KR101810290B1 (en) * 2015-07-08 2017-12-18 최원형 A composition for treating or preventing tuberculosis comprising Conjugated(9Z,11E)-Linoleic acid
KR101810292B1 (en) * 2015-07-08 2017-12-18 최원형 A composition for treating or preventing tuberculosis comprising Conjugated(10E,12Z)-Linoleic acid
KR101810291B1 (en) * 2015-07-08 2017-12-18 최원형 A composition for treating or preventing tuberculosis comprising Conjugated(9E,11E)-Linoleic acid
US11433012B2 (en) 2017-11-14 2022-09-06 Conopco, Inc. Peptides for increasing melanin in melanocytes
EP3720414A1 (en) 2017-12-06 2020-10-14 Unilever N.V. A skin darkening composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006239A (en) * 1974-04-11 1977-02-01 Bayer Aktiengesellschaft Benzoic acid amides for mycobacterium infections
US4355109A (en) * 1979-04-23 1982-10-19 Zajic James E Microbiological production of novel biosurfactants
EP0819380A1 (en) * 1996-06-07 1998-01-21 Iwao Hishida Bacteriocidal, antibacterial and bacteriostatic composition
WO2002034203A2 (en) * 2000-10-23 2002-05-02 Wellesley College Novel derivatives of phenyl 4-aminosalicylate and method of making the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006239A (en) * 1974-04-11 1977-02-01 Bayer Aktiengesellschaft Benzoic acid amides for mycobacterium infections
US4355109A (en) * 1979-04-23 1982-10-19 Zajic James E Microbiological production of novel biosurfactants
EP0819380A1 (en) * 1996-06-07 1998-01-21 Iwao Hishida Bacteriocidal, antibacterial and bacteriostatic composition
WO2002034203A2 (en) * 2000-10-23 2002-05-02 Wellesley College Novel derivatives of phenyl 4-aminosalicylate and method of making the same

Also Published As

Publication number Publication date
WO2004062607A2 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
WO2004062607A3 (en) Use of weak acids or their precursors for the treatment of tuberculosis (tb) and drug resistant tb
AU2003256755A1 (en) Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
NZ603319A (en) Diabetes therapy
DE122007000056I1 (en) Beta-amino-tetrahydroimidazo (1,2-A) pyrazines and -tetrahydrotriazolo (4,3-A) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
WO2006128022A3 (en) Solid compositions and methods for treating middle-of-the night insomnia
WO2010011375A3 (en) Inhibitors of janus kinases
WO2004006906A3 (en) Methods for the treatment of neoplasms
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2005107726A3 (en) Method for the treatment of back pain
NO20010743L (en) Antiviral indoloxoacetyl-piperazine derivatives
WO2004103297A3 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
TNSN05265A1 (en) Composition comprising a pde4 inhibitor and a pde5 inhibitor
WO2006113718A3 (en) Compositions for the treatment of neoplasms
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
WO2005004854A3 (en) Use of betaine for treating arteritis
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2005107467A3 (en) Compositions including opioids and methods of their use in treating pain
UA87312C2 (en) COMPOSITION FOR AEROSOL INHALATION OF β-AGONISTS
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
EP1695969A4 (en) Alpha-amino acid derivatives and use thereof as medicines
EP1603595A4 (en) Pharmaceutical composition for treatment of drug dependence
WO2006071564A3 (en) Aminium salts of 1,2,3-triazoles as prodrugs of drugs including antiviral agents
WO2005123113A3 (en) Interferon compositions and methods of use thereof
WO2003059395A3 (en) Antisense compounds directed against human csf-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase